Policy & Coverage

TrumpRx and GLP-1 Medications: What the Policy Actually Means for Patients

6 min read · Published 2026-04-19 · Sources cited to FDA / NIH / clinical trials

The executive order informally called "TrumpRx," signed in May 2025, directs the federal government to pursue Most-Favored-Nation (MFN) drug pricing — meaning the U.S. would pay no more for prescription drugs than the lowest price paid by other wealthy nations. For GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound — some of the most expensive and widely used drugs in America — this policy could meaningfully change what patients pay, but the timeline and real-world impact remain uncertain.

What Is the TrumpRx Executive Order?

On May 12, 2025, President Trump signed an executive order directing federal agencies, including the Department of Health and Human Services (HHS), to implement Most-Favored-Nation pricing for prescription drugs. The core idea is straightforward: if Germany, Japan, or Canada pays a certain price for semaglutide, the U.S. should not pay significantly more.

The order instructs HHS to pursue direct negotiations with pharmaceutical manufacturers and to establish a mechanism for importing drugs from countries where prices are lower. It builds on — but goes further than — the Inflation Reduction Act's Medicare Drug Negotiation Program, which CMS launched in 2023 and which allows Medicare to negotiate prices on a limited list of high-spend drugs.

Importantly, executive orders are directives to federal agencies, not laws passed by Congress. Their implementation depends on regulatory rulemaking, legal challenges from pharmaceutical companies, and cooperation from manufacturers — all of which take time.

Why Do GLP-1 Medications Matter in This Debate?

GLP-1 receptor agonists are among the fastest-growing drug categories in U.S. healthcare spending. Wegovy (semaglutide 2.4 mg) carries a list price of approximately $1,350 per month in the U.S. The same molecule costs roughly $140–$200 per month in Germany and the United Kingdom, according to published international price comparisons cited in Congressional testimony in 2024.

GLP-1s are prescribed for two primary FDA-approved indications:

  • Type 2 diabetes management — Ozempic (semaglutide) and Mounjaro (tirzepatide) carry this indication per their FDA labeling.
  • Chronic weight management — Wegovy (semaglutide) and Zepbound (tirzepatide) are FDA-approved for adults with obesity or overweight with at least one weight-related condition.

The SELECT Trial (Lincoff et al., NEJM 2023) also established that Wegovy reduces major cardiovascular events by 20% in people with obesity and established cardiovascular disease — a finding that has intensified the argument for broader insurance coverage and, by extension, affordability.

The most important thing to understand right now: The TrumpRx executive order does not immediately lower the price you pay at the pharmacy. Real price changes require regulatory rulemaking or manufacturer agreements that have not yet occurred as of mid-2025. Do not adjust or stop your medication based on anticipated savings that have not yet materialized.

How Might This Policy Affect GLP-1 Access Over Time?

The pathway from executive order to patient savings involves several steps, and each step carries uncertainty. The table below reflects the general policy progression as understood from public government statements and regulatory precedent — not confirmed implementation dates.

Timeframe Expected Policy Milestone Likely Patient Impact
0–6 months (mid-2025) HHS issues guidance; negotiations with manufacturers begin No change at pharmacy; awareness increases
6–18 months Proposed rulemaking published; legal challenges likely filed by pharma Potential court injunctions could delay or block rules
18–36 months Final rules published if not enjoined; manufacturer agreements sought Possible list price reductions for Medicare patients first
3+ years Broader private insurance and out-of-pocket impact if policy survives Commercially insured and uninsured patients may see lower costs

What About Compounded GLP-1s — Does This Policy Change Anything?

During the 2023–2024 shortage of semaglutide and tirzepatide, the FDA permitted compounding pharmacies to produce copies of these drugs under shortage exemptions. In early 2025, the FDA declared the shortage resolved and began enforcement action against compounders, per FDA statements published in 2025.

The TrumpRx executive order does not address compounding directly. However, if MFN pricing successfully lowers the cost of branded GLP-1s, the financial incentive to use compounded versions would decrease. For now, compounded semaglutide and tirzepatide remain legally restricted to specific circumstances, and patients should confirm their medication's source with their prescriber or pharmacist.

What Should Patients Do Right Now?

Policy timelines are long, but your prescription needs are immediate. Here are practical steps based on current reality:

  • Do not stop your medication in anticipation of future price drops. Abrupt discontinuation of GLP-1 therapy is associated with weight regain and blood glucose changes, per FDA prescribing information for both Wegovy and Zepbound.
  • Check manufacturer savings programs. Novo Nordisk and Eli Lilly both offer patient assistance programs and savings cards that can reduce out-of-pocket costs today, independent of any new policy.
  • Review your Medicare Part D coverage. Under the Inflation Reduction Act, out-of-pocket costs for Medicare Part D enrollees are capped at $2,000 annually starting in 2025 — a separate, already-enacted benefit that applies now.
  • Ask about biosimilar options. As GLP-1 biosimilars move through the FDA pipeline, competition may reduce prices independent of this executive order.
  • Talk to your prescriber if cost is causing you to skip doses or ration medication. There may be covered alternatives or assistance programs you are not currently using.

Frequently Asked Questions

No. As of mid-2025, the executive order has not changed what patients pay at the pharmacy. Real price reductions require regulatory rulemaking and manufacturer agreements that have not yet been finalized, so you should not expect lower prices immediately based on this policy alone.
Most-Favored-Nation pricing means the U.S. government would aim to pay no more for a drug than the lowest price paid by other wealthy countries. For a medication like Wegovy, which costs around $1,350 per month in the U.S. but roughly $140–$200 per month in Germany or the UK, this could eventually represent a very significant reduction — but only if the policy is fully implemented.
The timeline is uncertain. The policy must go through regulatory rulemaking, potential legal challenges from pharmaceutical manufacturers, and negotiation processes before prices can change. Based on how similar policies have progressed in the past, meaningful patient-level savings are unlikely to arrive sooner than one to several years from the order's signing.
The executive order primarily directs federal agencies and builds on Medicare's existing drug negotiation authority under the Inflation Reduction Act. Its direct reach is through federal programs like Medicare, though broader market effects on private insurance pricing are possible over time if manufacturer prices are formally renegotiated.
No. You should never stop or adjust a prescribed medication based on anticipated savings that have not yet materialized. If cost is a concern right now, speak with your prescriber or pharmacist about manufacturer savings programs, patient assistance options, or therapeutic alternatives that may be covered by your insurance.
GLP-1 receptor agonists are FDA-approved for two main conditions: type 2 diabetes management (Ozempic and Mounjaro) and chronic weight management in adults with obesity or overweight with at least one weight-related health condition (Wegovy and Zepbound). Wegovy also has evidence supporting cardiovascular risk reduction in people with obesity and established heart disease, based on the SELECT Trial published in the New England Journal of Medicine in 2023.
Yes, legal challenges are considered likely. Pharmaceutical manufacturers have previously sued to block government drug pricing measures, and executive orders are not laws passed by Congress, meaning their implementation can be slowed or overturned through the courts or regulatory processes. This legal uncertainty is one reason why the timeline for any real price changes remains unclear.
Sources
  • Executive Order on Delivering Most-Favored-Nation Prescription Drug Pricing, May 12, 2025 (White House)
  • Medicare Drug Price Negotiation Program, Centers for Medicare & Medicaid Services (CMS), 2024
  • Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER Trial), Marso et al., NEJM 2016
  • Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT Trial), Lincoff et al., NEJM 2023
  • FDA Prescribing Information: Wegovy (semaglutide injection), Novo Nordisk, 2021 (updated 2024)
  • FDA Prescribing Information: Zepbound (tirzepatide injection), Eli Lilly, 2023
  • Inflation Reduction Act Medicare Drug Negotiation, CMS.gov, 2023
  • FDA Statement on Compounded Semaglutide and Tirzepatide Shortage Status, 2024-2025

Keep Reading

Does Medicare Cover Wegovy or Zepbound in 2026Policy & Coverage · 7 min readGLP-1 Coverage Under the Inflation Reduction Act: What ChangedPolicy & Coverage · 7 min read

This site provides general information only and does not constitute medical advice. All content is sourced to FDA labeling, NIH publications, or peer-reviewed clinical trials. Always consult your prescriber before making any medication decision.